Q4 Earnings Forecast for KALV Issued By Leerink Partnrs

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities research analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for shares of KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will earn ($0.77) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Jones Trading reaffirmed a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $12.34 on Friday. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $15.50. The stock has a market capitalization of $613.50 million, a P/E ratio of -3.39 and a beta of 0.76. The company’s 50-day moving average is $10.49 and its 200 day moving average is $10.26.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, with a total value of $382,873.32. Following the completion of the acquisition, the insider now owns 4,986,480 shares of the company’s stock, valued at approximately $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the sale, the insider now owns 100,334 shares in the company, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders purchased 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals during the 4th quarter valued at about $44,000. Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 5,502 shares during the period. Legal & General Group Plc raised its stake in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 1,494 shares during the last quarter. Martin Worley Group bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).